Do you want to read an article? Please log in or register.
Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma
Lymphoma
Related content
Lymphoma
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
Eur J Cancer
Anota A, Basset M, Charton E, Bommier C, Efficace F, Dupuis J, Cottone F, Bouabdallah KK, Mollevi C, Ysebaert L, Winter A, Bijou F, Préau M, Chauchet A, Bernier A, Fornecker LM, Hafirassou H, Carras S, Lachenal F, Lionne-Huyghe P, Detourmignies L, Leyronnas C, Drénou B, Peyrou SLG, Abraham J, Monnereau A, Fouillet L, Morschhauser F, Rossi C, Belot A, Ghesquières H
doi: 10.1016/j.ejca.2024.114210
Lymphoma
Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL
Lymphoma
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis
Blood
Abro B, Maurer MJ, Habermann TM, Burack R, Chapman JR, Cohen JB, Friedberg JW, Inghirami GG, Kahl BS, Larson MC, Link BL, Lossos IS, Martin P, McDonnell T, Nastoupil LJ, Riska S, Syrbu SI, Vega F, Vij K, Flowers CR, Cerhan JR, Jaye DL, Feldman AL
doi: 10.1182/blood.2024025681
ASCO 2024
Genitourinary Cancer
Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC
ASH 2024
Lymphoma
Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement
Further Publications
Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients
Eur Radiol
Nelles C, Gräf M, Bernard P, Persigehl T, Große Hokamp N, Zopfs D, Maintz D, Kreuzberg N, Wolf J, Bröckelmann PJ, Lennartz S
doi: 10.1007/s00330-024-11060-4
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
ASH 2024
Lymphoma
A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma
ASH 2024
Lymphoma